- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01410513
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Primary Objective:
- To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for SAR245409 when administered in combination with rituximab or bendamustine plus rituximab
Secondary Objectives:
- To determine the safety and tolerability of SAR245409 in combination with rituximab or bendamustine plus rituximab in subjects with indolent Hon-Hodgkin Lymphoma (iNHL) Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)
- To determine the pharmacokinetics (PK) of SAR245409, bendamustine and rituximab when used in combination in subjects with iNHL, MCL or CLL
- To determine the pharmacodynamic (PD) effects of SAR245409 in combination with rituximab or bendamustine plus rituximab in subjects with iNHL, MCL or CLL
- To determine the antitumor activity of SAR245409 in combination with rituximab or bendamustine plus rituximab in subjects with iNHL, MCL or CLL
Study Overview
Status
Intervention / Treatment
Detailed Description
All subjects will take SAR245409 twice daily. All subjects will receive SAR245409 as long as there is clinical benefit.
Combination therapy with SAR245409, bendamustine and rituximab , will be administered over a 28 day cycle for up to 6 to 8 cycles.
Subjects receiving the doublet combination , SAR245409 plus rituximab will receive weekly rituximab for 4 - 8 weeks. Monthly Rituximab may be continued beyond 8 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Investigational Site Number 840004
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Investigational Site Number 840006
-
-
South Carolina
-
Charleston, South Carolina, United States, 29406
- Investigational Site Number 840002
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- A confirmed diagnosis of indolent non-Hodgkin lymphoma, mantle cell lymphoma or chronic lymphocytic leukemia
- Evaluable disease or measurable disease
- Transfusion independent
- Able to take oral medication
- Male and Female subjects > 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Women of childbearing potential using adequate contraception
Exclusion criteria:
- Prior therapy with a PI3K, mTOR or dual PI3K/mTOR inhibitor resulting in adverse events necessitating treatment discontinuation
- Eligible for a hematopoietic stem cell transplant (HSCT)
- The subject has received investigational or non-investigational cytotoxic chemotherapy (i.e., cyclophosphamide), small molecule cancer therapy (i.e., imatinib), biologic cancer therapies other than rituximab (i.e., alemtuzumab, cytokines, vaccines or other monoclonal antibodies) hormonal therapy, radio- or immuno- conjugates (e.g. ibritumomab tiuxetan, tositumomab) or immunosuppressants to treat malignancy within 4 weeks prior to Cycle 1, Day 1
- Radiation therapy within 2 weeks prior to Cycle 1, Day 1
- Autologous Hematopoietic Stem Cell Transplant (HSCT) within the past 16 weeks
- Prior allogeneic HSCT
- Active central nervous system (CNS) metastases or leptomeningeal involvement
- Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C Antibody (anti-HCV)
- Hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus (HIV) infection
- Active peptic ulcer disease requiring treatment with proton pump inhibitors (e.g. pantoprazole) or Type 2 histamine antagonists (e.g. cimetidine)
- Diagnosis or treatment for another malignancy within 3 years of enrollment with the exception of complete resection of basal cell or squamous cell carcinoma of the skin, an in situ malignancy or low-risk prostate cancer after curative therapy
- Inadequate bone marrow function
- Abnormal liver function
- Abnormal renal function
- Abnormal coagulation
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SAR245409 + rituximab
Subjects will receive oral SAR245409 twice daily continuously and weekly rituximab intravenously
|
Pharmaceutical form:capsule Route of administration: oral
|
EXPERIMENTAL: SAR245409 + rituximab + bendamustine (iNHL, MCL)
Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine intravenously.
|
Pharmaceutical form:capsule Route of administration: oral
|
EXPERIMENTAL: SAR245409 + rituximab+ bendamustine (CLL)
Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine and rituximab intravenously
|
Pharmaceutical form:capsule Route of administration: oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Identification Of Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)
Time Frame: 4 weeks to 8 weeks
|
4 weeks to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with treatment emergent adverse events
Time Frame: Time from receiving first dose of SAR245409 until 30 days after the last dose
|
Time from receiving first dose of SAR245409 until 30 days after the last dose
|
Pharmacokinetics (Cmax) of SAR245409
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (tmax) of SAR245409
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (AUC0-12h) of SAR245409
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (Ctrough) of SAR245409
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (AUC) of bendamustine
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (AUClast) of bendamustine
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (Ceoi) of bendamustine
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (tmax) of bendamustine
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (Cl) of bendamustine
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (Vss) of bendamustine
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (AUC0-7h) of rituximab
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (Ceoi) of rituximab
Time Frame: up to 2 months
|
up to 2 months
|
Pharmacokinetics (tmax) of rituximab
Time Frame: up to 2 months
|
up to 2 months
|
Efficacy as determined by objective response rate (ORR)
Time Frame: up to 4 years
|
up to 4 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCD12012
- U1111-1119-2906 (OTHER: UTN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mantle Cell Lymphoma
-
Northwestern UniversityNational Cancer Institute (NCI); Janssen Scientific Affairs, LLCActive, not recruitingStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma | Stage II Contiguous Mantle Cell Lymphoma | Stage II Non-Contiguous Mantle Cell LymphomaUnited States
-
Burzynski Research InstituteWithdrawnRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell LymphomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Ann Arbor Stage I Mantle Cell Lymphoma | Ann Arbor Stage II Mantle Cell Lymphoma | Ann Arbor Stage III Mantle Cell Lymphoma | Ann Arbor Stage IV Mantle Cell LymphomaUnited States
-
BeiGeneRecruitingMantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina, Puerto Rico
-
BeiGeneCompletedRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaChina
-
Fondazione Italiana Linfomi - ETSRecruitingRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaItaly
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Central Nervous System Lymphoma | Gastric Mantle Cell Lymphoma | Splenic Mantle Cell LymphomaUnited States
Clinical Trials on SAR245409
-
SanofiCompletedLymphomaGermany, France, Belgium, Netherlands, United States, Australia
-
SanofiCompletedNeoplasm MalignantUnited States
-
SanofiCompletedCancerUnited States, Spain
-
SanofiCompletedGlioblastoma | Astrocytoma, Grade IVUnited States
-
EMD SeronoSanofiCompletedOvarian CancerUnited States, Belgium, Canada, Australia, Spain, France, Poland
-
SanofiCompletedNeoplasm MalignantSpain, Belgium, United States, France
-
SanofiCompletedCancer | Non-Small Cell Lung CancerUnited States
-
SanofiCompletedGlioblastoma Multiforme | Malignant Gliomas | Mixed GliomasUnited States
-
SanofiCompletedBreast CancerUnited States, France, Spain
-
EMD SeronoSanofiCompletedMelanoma | Breast Cancer | Colorectal Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid TumorUnited States, Italy, Spain